Program
SHR-7787
A development code. Also written as “SHR-7787 injection”.
In Jiangsu HengRui Medicine's pipeline, DLL3/CD3
. Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Sep 14, 20241 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Sep 14, 2024 | Sep 14, 2024 | Dec 2026phase 2 · NCT06605222 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-7787
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2024First study: phase 2 study in Advanced Solid TumorsFirst studyNCT06605222 · 201 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT06605222
TargetBeta
“DLL3/CD3”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06605222Advanced Solid Tumors · China | 2 | Recruiting | Dec 2026 | 201 |
How it is read
Names in the registry
- “SHR-7787 injection”, 1 entry
Codes read as this program: SHR7787.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.